*The following content is generated by AI and is for reference only.
Bedaquiline, marketed under the brand name Sirturo, represents a landmark advancement in the global fight against drug-resistant tuberculosis (TB). Chemically identified by the CAS number 857804-39-6, this synthetic diarylquinoline compound possesses the molecular formula C27H31F2N3OS. Its unique structure allows it to penetrate mycobacterial cells effectively, distinguishing it from traditional anti-TB agents like rifampin or isoniazid.
The primary clinical utility of Bedaquiline lies in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB), particularly when standard regimens have failed or are insufficient. It functions as a potent inhibitor of the mycobacterial ATP synthase enzyme, specifically targeting the c-subunit of the F0 portion. By blocking this critical energy-producing mechanism, the drug starves the bacteria of adenosine triphosphate (ATP), leading to bacterial death rather than mere growth inhibition. This novel mode of action has revitalized treatment protocols for difficult-to-cure cases, significantly improving patient outcomes where previous options were limited.
Regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved Bedaquiline as part of combination therapy for adult patients with MDR-TB. It is strictly indicated for use alongside other effective anti-tuberculosis medications to prevent the emergence of further resistance. While its introduction marked a major therapeutic breakthrough, clinicians must monitor for potential adverse effects, including QT interval prolongation, hepatotoxicity, and musculoskeletal issues. Despite these risks, Bedaquiline remains a cornerstone in modern MDR-TB management strategies, offering hope for patients facing life-threatening infections that were previously considered nearly untreatable. Ongoing research continues to explore its efficacy in pediatric populations and shorter treatment durations, aiming to streamline care while maintaining high cure rates globally.